001     120555
005     20240228145452.0
024 7 _ |a 10.1093/carcin/bgx004
|2 doi
024 7 _ |a pmid:28426874
|2 pmid
024 7 _ |a 0143-3334
|2 ISSN
024 7 _ |a 1460-2180
|2 ISSN
024 7 _ |a altmetric:19232363
|2 altmetric
037 _ _ |a DKFZ-2017-00984
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Yang, Rongxi
|0 P:(DE-He78)dd35af1fb84ec0812fe4bdea97d2f291
|b 0
245 _ _ |a The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies.
260 _ _ |a Oxford
|c 2017
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1661255263_31348
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Breast cancer (BC) is the leading cancer in women worldwide. Changes in DNA methylation in peripheral blood could be associated with malignant diseases. Making use of screening results by llumina 27K Methylation Assay, we validated demethylation of five CpG sites of S100P gene in blood cell DNA of BC patients by three independent retrospective studies with subjects from different centers (Validation I: 235 familial BC case and 206 controls, odds ratio per -1% methylation > 1.03, and P < 6.00 × 10-8 for all five CpG sites; Validation II: 189 sporadic BC case and 189 controls, odds ratio per -1% methylation > 1.03, P < 8.0 × 10-5 for four CpG sites; Validation III: 156 sporadic BC case and 151 controls, odds ratio per -1% methylation > 1.03, P < 6.0 × 10-4 for four CpG sites). In addition, the blood-based S100P methylation pattern was similar among BC patients with differential clinical characteristics regardless of stage, receptor status and menopause status. The observed BC-associated decreased S100P methylation in blood mainly originates from the leucocytes subpopulations but not B cells. The methylation levels of most S100P CpG sites were inversely correlated with the expression of S100P in leucocytes (P < 1.2 × 10-4) and in tissue (P < 1.1 × 10-4). This study reveals significant association between blood-based decreased S100P methylation and BC, and provides another proof for the application of altered DNA methylation signatures from blood cells as potential markers for the detection of BC, especially for the early stage.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Stöcker, Sarah
|0 P:(DE-He78)f0a01df447f74d4e57b596d985130a15
|b 1
700 1 _ |a Schott, Sarah
|b 2
700 1 _ |a Heil, Jörg
|b 3
700 1 _ |a Marme, Frederik
|b 4
700 1 _ |a Cuk, Katarina
|0 P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a
|b 5
700 1 _ |a Chen, Bowang
|0 P:(DE-He78)8220e47f6459dc55316cf6b06b0eec3b
|b 6
700 1 _ |a Golatta, Michael
|b 7
700 1 _ |a Zhou, Yan
|b 8
700 1 _ |a Sutter, Christian
|b 9
700 1 _ |a Wappenschmidt, Barbara
|b 10
700 1 _ |a Schmutzler, Rita
|b 11
700 1 _ |a Bugert, Peter
|b 12
700 1 _ |a Qu, Bin
|b 13
700 1 _ |a Bartram, Claus R
|b 14
700 1 _ |a Sohn, Christof
|b 15
700 1 _ |a Schneeweiss, Andreas
|0 P:(DE-He78)2dc788b30e99b99a3f9b45ca60f3939d
|b 16
700 1 _ |a Burwinkel, Barbara
|0 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
|b 17
|e Last author
773 _ _ |a 10.1093/carcin/bgx004
|g Vol. 38, no. 3, p. 312 - 320
|0 PERI:(DE-600)1474206-8
|n 3
|p 312 - 320
|t Carcinogenesis
|v 38
|y 2017
|x 1460-2180
909 C O |p VDB
|o oai:inrepo02.dkfz.de:120555
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 0
|6 P:(DE-He78)dd35af1fb84ec0812fe4bdea97d2f291
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)f0a01df447f74d4e57b596d985130a15
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)8220e47f6459dc55316cf6b06b0eec3b
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 16
|6 P:(DE-He78)2dc788b30e99b99a3f9b45ca60f3939d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)15b7fd2bc02d5ef47a2fe2dd0140d2bf
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2017
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CARCINOGENESIS : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C080-20160331
|k C080
|l Molekulare Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)C050-20160331
|k C050
|l Molekular-Genetische Epidemiologie
|x 1
920 1 _ |0 I:(DE-He78)V964-20160331
|k V964
|l NCT-KliHD
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C080-20160331
980 _ _ |a I:(DE-He78)C050-20160331
980 _ _ |a I:(DE-He78)V964-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21